Meningococcal B vaccine acceptability: Results of a longitudinal study in Quebec (Canada)

[1]  B. Sander,et al.  The Health Burden of Invasive Meningococcal Disease: A Systematic Review. , 2016, Journal of the Pediatric Infectious Diseases Society.

[2]  J. Langley,et al.  Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network study. , 2016, Vaccine.

[3]  C. Chidiac,et al.  Vaccination against serogroup B Neisseria meningitidis: Perceptions and attitudes of parents. , 2015, Vaccine.

[4]  È. Dubé,et al.  Parents’ and adolescents’ willingness to be vaccinated against serogroup B meningococcal disease during a mass vaccination in Saguenay–Lac-St-Jean (Quebec) , 2015, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[5]  T. Clark,et al.  First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak , 2015, Pediatrics.

[6]  S. Bambini,et al.  Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives , 2015, Expert review of vaccines.

[7]  M. Faccini,et al.  Acceptability of meningococcal serogroup B vaccine among parents and health care workers in Italy: A survey , 2014, Human vaccines & immunotherapeutics.

[8]  B. Sander,et al.  164: The Health Burden of Invasive Meningococcal Disease: A Systematic Review , 2014 .

[9]  H. Marshall,et al.  Parental and community acceptance of the benefits and risks associated with meningococcal B vaccines. , 2014, Vaccine.

[10]  D. Medini,et al.  Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). , 2013, Vaccine.

[11]  Natalie J. Carter.  Multicomponent Meningococcal Serogroup B Vaccine (4CMenB; Bexsero®): A Review of its Use in Primary and Booster Vaccination , 2013, BioDrugs.

[12]  W. Edmunds,et al.  The Effect of Perceived Risks on the Demand for Vaccination: Results from a Discrete Choice Experiment , 2013, PloS one.

[13]  S. Halperin,et al.  The Disease Burden of Invasive Meningococcal Serogroup B Disease in Canada , 2013, The Pediatric infectious disease journal.

[14]  M. Rose,et al.  Health care providers’ and parents’ attitudes toward administration of new infant vaccines—a multinational survey , 2012, European Journal of Pediatrics.

[15]  B. Lefebvre,et al.  The Changing Epidemiology of Meningococcal Disease in Quebec, Canada, 1991–2011: Potential Implications of Emergence of New Strains , 2012, PloS one.

[16]  D. Mak,et al.  Paediatric influenza vaccination program suspension: effect on childhood vaccine uptake , 2012, Australian and New Zealand journal of public health.

[17]  P. Baghurst,et al.  Parental views on vaccine safety and future vaccinations of children who experienced an adverse event following routine or seasonal influenza vaccination in 2010 , 2012, Human vaccines & immunotherapeutics.

[18]  Ly-Mee Yu,et al.  Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. , 2012, JAMA.

[19]  Diane P. Martin,et al.  Validity and reliability of a survey to identify vaccine-hesitant parents. , 2011, Vaccine.

[20]  K. Beusterien,et al.  Parent Preferences for Pediatric Influenza Vaccine Attributes , 2011, Clinical pediatrics.

[21]  Diane P. Martin,et al.  Development of a survey to identify vaccine-hesitant parents , 2011, Human vaccines.

[22]  E. Puijenbroek,et al.  Fever Following Immunization with Influenza A (H1N1) Vaccine in Children , 2010, Drug Safety.

[23]  S. Clark,et al.  Parental Vaccine Safety Concerns in 2009 , 2010, Pediatrics.

[24]  B. Schwartz,et al.  Parents With Doubts About Vaccines: Which Vaccines and Reasons Why , 2008, Pediatrics.

[25]  Helen Bedford,et al.  More vaccines for children? Parents' views. , 2007, Vaccine.

[26]  J. Yarwood,et al.  Meningococcal B: tell me everything you know and everything you don't know. New Zealanders' decision-making regarding an immunisation programme. , 2007, The New Zealand medical journal.

[27]  P. De Wals,et al.  Invasive Meningococcal Disease in Québec, Canada, Due to an Emerging Clone of ST-269 Serogroup B Meningococci with Serotype Antigen 17 and Serosubtype Antigen P1.19 (B:17:P1.19) , 2006, Journal of Clinical Microbiology.